Cargando…
Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a major limitation for long-term survival of patients undergoing heart transplantation (HT). Some immunosuppressants can reduce the risk of CAV. OBJECTIVES: The primary objective was to evaluate the variation in the volumetric growth of the intimal...
Autores principales: | Wang, Ricardo, Moura, Lidia Ana Zytynski, Lopes, Sergio Veiga, da Costa, Francisco Diniz Affonso, Souza Filho, Newton Fernando Stadler, Fernandes, Tiago Luiz, Salvatti, Natália Boing, Faria Neto, José Rocha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Cardiologia
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559127/ https://www.ncbi.nlm.nih.gov/pubmed/26107815 http://dx.doi.org/10.5935/abc.20150063 |
Ejemplares similares
-
Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
por: Koch, Martina, et al.
Publicado: (2009) -
Risk factors of cardiac allograft vasculopathy
por: Szyguła-Jurkiewicz, Bożena, et al.
Publicado: (2015) -
Efficacy of basiliximab induction in poorly matched living donor renal transplantation
por: Gundlapalli, S., et al.
Publicado: (2013) -
Early Cardiac Allograft Vasculopathy: Are the Viruses to Blame?
por: Aggarwal, Ashim, et al.
Publicado: (2012) -
Cardiac allograft vasculopathy: diagnosis, therapy, and prognosis
por: Skorić, Boško, et al.
Publicado: (2014)